argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?
argenx SE (NASDAQ:ARGX) delivered a clearly positive headline result from the Phase 3 ALKIVIA trial.
Argenx Se (ARGX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 1,000,000 | $927,770,000 | 8.33% | |
| 2. | Citadel Investment Group Ken Griffin | 212,416 | $197,073,193 | -4% | 0.02% |
| 3. | BAMCO Inc. Ron Baron | 136,654 | $126,783,482 | -2% | 0.19% |
| 4. | Checkpoint Capital Sam Huang | 131,283 | $121,800,429 | -15% | 31.25% |
| 5. | Millennium Management Israel Englander | 94,401 | $87,582,416 | +31% | 0.03% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,144 | $1,096,535 | 0.02% | |
| 2. | 684 | $655,894 | 0.07% | |
| 3. | 632 | $606,032 | 0.06% | |
| 4. | 459 | $440,140 | 0.01% | |
| 5. | 414 | $396,989 | 0.03% |
News See All
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?
Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults...
Argenx SE (ARGX) Stock Soars 15% on Positive Phase 3 Study Results
Argenx SE stock was up 15.25% on Monday after the company posted results from its ALKIVIA Phase 3 study.
Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences
argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price.
Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here.
argenx Bets $2.2 Billion on a Vitiligo Breakthrough: What the Forte Biosciences Deal Means for Both Stocks
The biopharma sector is in the middle of a transformation in which macroeconomic pressures and policy developments actively dictate corporate dealmaking.
Beyond Consensus: Earnings Surprises That Shook Wall Street Yesterday
As over 150 companies released their second-quarter earnings on July 23, investors were still absorbing the headline economic event of the day as the US Trade Representative announced new 10% to 12.5% ...
12 Most Promising Growth Stocks to Buy Now
In this article, we will discuss the 12 Most Promising Growth Stocks to Buy Now. Technology stocks are flashing bearish signals as a rotation from all-time highs gathers pace.
10 Best European Growth Stocks to Buy
In this article, we will look at the 10 Best European Growth Stocks to Buy. European growth stocks are getting another look as investors search for earnings growth outside the usual U.S.
8 Most Promising Biotech Stocks to Buy Now
In this article, we will discuss: 8 Most Promising Biotech Stocks to Buy Now.